Canadian Cancer Trials Group Bulletins


Recent Publications

Canadian Cancer Trials Group OV.19 (MRC ICON7) - A Randomized, Two-Arm, Multi-Centre Gynecologic Cancer Intergroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin And Paclitaxel) in Patients with Epithelial Ovarian Cancer

Results from Canadian Cancer Trials Group OV.19 (ICON7) showed that bevacizumab improved progression-free survival in patients with ovarian cancer when used in combination with first-line chemotherapy and as a single-drug continuation treatment for 18 cycles. In a preliminary analysis of a high-risk subset of patients, there was also an improvement in overall survival.

In this study, the authors were interested in health-related quality-of-life (QoL) outcomes and found that bevacizumab continuation treatment seems to be associated with a small but clinically significant decrement in QoL compared with standard treatment for women with ovarian cancer. They suggest that the trade-off between the prolongation of progression-free survival and the quality of that period of time needs to be considered in clinical practice when making treatment decisions.

Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, Hilpert F, Cervantes A, Brown J, Lanceley A, Velikova G, Sabate E, Pfisterer J, Carey MS, Beale P, Qian W, Swart AM, Oza A, Perren T. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial (ONLINE). The Lancet Oncology 2013.

Comment Article:


Chapman JW, O'Callaghan CJ, Hu N, Ding K, Yothers GA, Catalano PJ, Shi Q, Gray RG, O'Connell MJ, Sargent DJ. Innovative estimation of survival compared to standard using Adjuvant Colon Cancer Endpoints (ACCENT) database (ONLINE). Br J Cancer 2013.